EBX-102 is under clinical development by Enterobiotix and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EBX-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EBX-102 overview
EBX-102 is under development for the treatment of antibiotic resistant bacterial infections, blood cancers including acute lymphocytic leukemia, acute myelocytic leukemia, myelodysplastic syndrome, chronic myelocytic leukemia (CML) and chronic myelomonocytic leukemia ((CMML)), liver cirrhosis, hepatic Encephalopathy and irritable bowel syndrome (IBS). The therapeutic candidate comprises of donar derived microbiota combined with precision antimicrobials. The therapeutic candidate is administred by oral route in the form of capsule. The therapy is being developed based on faecal microbiota transplantation based manipulated microbiota platform and AMPLA platform.
Enterobiotix overview
Enterobiotix Limited (Enterobiotix) is a developer of novel medicinal products intended to restore health and prevent bacterial infections. Enterobiotix is headquartered in Foresterhill
For a complete picture of EBX-102’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
